Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors

被引：1
|
作者：
Einama, Takahiro [1 ,4 ]
Kawamata, Futoshi [1 ]
Kamachi, Hirofumi [1 ]
Nishihara, Hiroshi [2 ]
Homma, Shigenori [1 ]
Matsuzawa, Fumihiko [1 ]
Mizukami, Tatsuzo [1 ]
Konishi, Yuji [1 ]
Kamiyama, Toshiya [1 ]
Yamamoto, Junji [4 ]
Taketomi, Akinobu [1 ]
Todo, Satoru [3 ]
机构：
[1] Hokkaido Univ, Grad Sch Med, Dept Gen Surg, Sapporo, Hokkaido 0608638, Japan
[2] Natl Hosp Org, Hokkaido Canc Ctr, Dept Pathol, Sapporo, Hokkaido 0030804, Japan
[3] St Marys Hosp, Res Inst, Kurume, Fukuoka 8308558, Japan
[4] Natl Def Med Coll, Dept Surg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan
来源：
EBIOMEDICINE | 2017年 / 24卷
关键词：
GASTRIC-CANCER; ERC/MESOTHELIN; ADENOCARCINOMA;
D O I：
10.1016/j.ebiom.2017.09.033
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [31] Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody
    Prantner, Andrew M.
    Yin, Catherine
    Kamat, Kalika
    Sharma, Khushboo
    Lowenthal, Andrew C.
    Madrid, Peter B.
    Scholler, Nathalie
    MOLECULAR PHARMACEUTICS, 2018, 15 (04) : 1403 - 1411
  • [32] The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
    Yi Yu
    Seby L Edassery
    Animesh Barua
    Jacques S Abramowicz
    Janice M Bahr
    Ingegerd Hellstrom
    Judith L Luborsky
    Journal of Ovarian Research, 4
  • [33] The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
    Yu, Yi
    Edassery, Seby L.
    Barua, Animesh
    Abramowicz, Jacques S.
    Bahr, Janice M.
    Hellstrom, Ingegerd
    Luborsky, Judith L.
    JOURNAL OF OVARIAN RESEARCH, 2011, 4
  • [34] Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells
    Dong-hui Wang
    Xiao-hua Wu
    Su-min Qian
    Hai-Rong Yao
    Medical Oncology, 2015, 32
  • [35] A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors
    Hung, Chien-Fu
    Calizo, Roanne
    Tsai, Ya-Chea
    He, Liangmei
    Wu, T-C
    VACCINE, 2007, 25 (01) : 127 - 135
  • [36] Erratum to: Study on the mesothelin-specific cytotoxicity against epithelial ovarian cancer with full-length mesothelin cDNA-transduced dendritic cells
    Dong-hui Wang
    Xiao-hua Wu
    Su-min Qian
    Hai-Rong Yao
    Medical Oncology, 2015, 32
  • [37] Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
    Cao, Bihui
    Liu, Manting
    Huang, Jingjun
    Zhou, Jingwen
    Li, Junping
    Lian, Hui
    Huang, Wensou
    Guo, Yongjian
    Yang, Shuo
    Lin, Liteng
    Cai, Mingyue
    Zhi, Cheng
    Wu, Jingqiang
    Liang, Licong
    Hu, Yuling
    Hu, Hong
    He, Jinping
    Liang, Baoxia
    Zhao, Qi
    Zhu, Kangshun
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (14): : 3850 - 3861
  • [38] Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors
    Molloy, Mary Ellen
    Austin, Richard J.
    Lemon, Bryan D.
    Aaron, Wade H.
    Ganti, Vaishnavi
    Jones, Adrie
    Jones, Susan D.
    Strobel, Kathryn L.
    Patnaik, Purbasa
    Sexton, Kenneth
    Tatalick, Laurie
    Yu, Timothy Z.
    Baeuerle, Patrick A.
    Law, Che-Leung
    Wesche, Holger
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1452 - 1462
  • [39] Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.
    Pegna, Guillaume Joe
    Ahmad, Mehwish Iqra
    Steinberg, Seth M.
    Peer, Cody J.
    Figg, William Douglas
    FitzGerald, David J. P.
    Hassan, Raffit
    Pastan, Ira
    Alewine, Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [40] Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents
    Schatz, Christoph A.
    Quanz, Maria
    Hagemann, Urs B.
    Zitzmann-Kolbe, Sabine
    Stelte-Ludwig, Beatrix
    Golfier, Sven
    Kopitz, Charlotte
    Elbi, Cem
    Ziegelbauer, Karl
    Mumberg, Dominik
    CANCER RESEARCH, 2018, 78 (13)
12345